Izumi Nagatomo

Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients

Akio Osa, Takeshi Uenami, Shohei Koyama et al. · JCI Insight · 2018 · 234 citations · Full text

Pharmacy, Immunology, Oncology +17

Impact of sarcopenia in patients with advanced non–small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study

Takayuki Shiroyama, Izumi Nagatomo, Shohei Koyama et al. · Scientific Reports · 2019 · 164 citations · Full text

Medicine, Oncology, Pharmacology +17

YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14

J-M Huang, Izumi Nagatomo, Emi Suzuki et al. · Oncogene · 2012 · 151 citations

Life Sciences, Molecular Biology, Oncology +12

Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape

Yoshiko Takeuchi, Tokiyoshi Tanegashima, Eiichi Sato et al. · Science Immunology · 2021 · 131 citations

Medicine, Immunology, Oncology +17

Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA

Junji Uchida, Kikuya Kato, Yoji Kukita et al. · Clinical Chemistry · 2015 · 112 citations · Full text

Medicine, Molecular Genetics, Oncology +17